Notably, BCR-PDGFRA, BCR-JAK2, and BCR-RET fusions have been established as additional drivers of myeloid and lymphoid neoplasms, while BCR-NTRK2 was identified as a potential driver of glioblastoma [45, 46]. Here, NTRK2 is linked to lymphoid neoplasm.